OIG subpoenas United Therapeutics paperwork

Share this article:

The Office of the Inspector General (OIG) of the Department of Health and Human Services is taking a gander at United Therapeutics and its marketing practices. The drugmaker announced Monday that the government agency subpoenaed  “documents regarding...the company's marketing practices relating” to its drugs Remodulin, Tyvaso and Adcirca. All are used to treat pulmonary arterial hypertension (PAH).

The "About Us" section of the OIG's website notes that the HHS Office of the Inspector General is the federal government's largest Office of Inspector General department, and is responsible for sussing out waste, fraud and abuse in HHS programs, which include Medicare and Medicaid, among others.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.